Posted: Monday, June 17, 2019
Sagar Lonial, MD, of Winship Cancer Institute of Emory University, discusses whether study findings should alter the standard approach of observation alone with lenalidomide treatment which may delay progression of asymptomatic high-risk smoldering multiple myeloma.